Ike­na inks small cash grab in all-stock deal for Pi­o­nyr to take can­cer drug on Hip­po path­way

Ike­na On­col­o­gy said it added about $43 mil­lion to its run­way af­ter mak­ing an all-stock ac­qui­si­tion of the pri­vate start­up Pi­o­nyr Im­munother­a­peu­tics, a clin­i­cal-stage com­pa­ny that Gilead de­cid­ed not to ful­ly buy out ear­li­er this year.

Ike­na had slimmed down its pipeline in No­vem­ber as the pub­licly trad­ed biotech went in­to cash-sav­ing mode like many of its peers in the in­dus­try.

Now, the stock-for-stock deal, an­nounced Mon­day morn­ing, al­lows Ike­na to keep pur­su­ing the so-called Hip­po path­way with its Phase I-stage IK-930. The ini­tial clin­i­cal da­ta are an­tic­i­pat­ed lat­er this year. The cash is al­so ex­pect­ed to bankroll bring­ing its MEK-RAF in­hibitor IK-595 in­to the clin­ic, and the com­pa­ny has plans to sub­mit an IND this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER